NCT06263478进行中（未招募）3 期
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
- 试验地点
- 28
- 主要终点
- Overall Response Rate in the First 6 Cycles
研究概览
简要总结
This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 6 years of age at the time of signing the ICF.
- •Ability to comprehend and willingness to sign a written ICF for the study.
- •For participants 6 to 17 years old, a parent/guardian must provide consent for pediatric participants; when applicable, pediatric participants should also sign an assent form.
- •Japanese participants who are allo-HSCT recipients with active, refractory, or recurrent cGVHD requiring systemic immune suppression despite at least 2 lines of prior systemic therapy.
- •Active cGVHD is defined as the presence of signs and symptoms of cGVHD per the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
- •Refractory disease is defined as meeting any of the following criteria:
- •The development of 1 or more new sites of disease while being treated for cGVHD.
- •Progression of existing sites of disease despite at least 1 month of standard or investigational therapy for cGVHD.
- •Participants who did not achieve a response within 3 months on prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
- •Recurrent cGVHD is defined as active, symptomatic disease (after an initial response to prior therapy) based on the NIH 2014 consensus criteria by organ-specific or global assessment or for which the physician believes a new line of systemic therapy is required.
- •Participants may have persistent, active aGVHD and cGVHD manifestations (overlap syndrome), as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
- •Karnofsky performance score of ≥ 60 (if aged 16 years or older); Lansky performance score of ≥ 60 (if aged younger than 16 years).
- •Adequate organ and bone marrow functions evaluated during the 14 days prior to the start of study treatment.
- •Creatinine clearance ≥ 30 mL/min based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants.
- •Concomitant use of a systemic corticosteroid is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking a corticosteroid, it must be a stable dose for at least 2 weeks prior to the start of study treatment.
- •Concomitant use of protocol-defined immunosuppressant is allowed but not required.
- •Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.
排除标准
- •Has aGVHD without manifestations of cGVHD.
- •Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
- •History of acute or chronic pancreatitis.
- •History of myositis.
- •History or other evidence of severe illness, uncontrolled infection, allergy to excipients, or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study.
- •Has acquired immunodeficiency syndrome.
- •History of latent or active TB based on protocol-defined criteria.
- •Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg).
- •Pregnant or breastfeeding.
- •Previous exposure to CSF-1R targeted therapies.
- •Use of any agent other than corticosteroids, or the immunosuppressant for the treatment of cGVHD within 2 weeks or 5 half-lives, whichever is shorter, prior to the start of study treatment.
- •Has received an investigational treatment within 28 days prior to the start of study treatment.
- •Currently participating in any other interventional study.
研究组 & 干预措施
Axatilimab Dose
Experimental
Axatilimab at the protocol-defined dose.
干预措施: INCA034176 (Drug)
结局指标
主要结局
Overall Response Rate in the First 6 Cycles
时间窗: Up to Cycle 7 (Day 169)
The overall response rate will be assessed by the number of participants with objective response by Cycle 7 (28-day cycles), Day 1, with responses defined by the 2014 NIH consensus criteria.
次要结局
- Number of Participants with Anti-Drug Antibody (ADA)(Up to 2 years and 30 days)
- Proportion of participants with a ≥ 7-point improvement in modified Lee symptom scale (mLSS) score(Up to 2 years)
- Overall Response Rate(Up to 2 years)
- Duration of Response(Up to 2 years)
- Organ-specific Response Rate(Up to 2 years)
- Percent reduction in average daily dose (or equivalent) of corticosteroids(Up to 2 years)
- Proportion of participants who discontinue corticosteroid use(Up to 2 years)
- Change from baseline in Karnofsky/Lansky performance status(Up to 2 years and 30 days)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)(Up to 2 years and 30 days)
- Axatilimab pharmacokinetic (PK) in Plasma(Up to 2 years and 30 days)
研究者
研究点 (28)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseNCT06388564Incyte Corporation130
招募中
3 期
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseNCT06585774Incyte Corporation240
进行中（未招募）
3 期
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Follicular LymphomaNCT05371093Kite, A Gilead Company231
进行中（未招募）
3 期
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseUlcerative ColitisCrohn's DiseaseNCT04738942Takeda57
已完成
3 期
A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.Colitis, UlcerativeNCT01863771Janssen Pharmaceutical K.K.144